Development and internal validation of a kinetic heterogeneity-based nomogram by dynamic contrast-enhanced magnetic resonance imaging to differentiate benign and malignant breast BI-RADS 4 lesions

Key Points

• The nomogram effectively differentiates between benign and malignant BI-RADS 4 breast lesions, enhancing clinical decision-making.
• Key evidence indicates that this tool may significantly reduce unnecessary breast biopsies, improving patient care.
• Prospective validation is warranted to ensure its reliability in clinical settings, enhancing diagnostic accuracy.
• Further external validation could solidify its role in routine clinical practice, directly impacting patient management.